Myeloma Minute: Your Chance to Win a Hawaiian Oasis Vacation

myelomaMinBanner3.28.19.jpg

| INSPIRATION | Raffle

540x270hawaii.jpg

A 10-Day Luxury Hawaiian Oasis Is a Winning Raffle Ticket Away

The IMF is hosting a raffle for you to win a 10-day stay at the Villa Ono Oasis in Hawaii. The dates of this paradise vacation are March 16-26, 2020. The winners of this luxury package will receive:

  • A 10-day stay at the Villa Ono Oasis
  • Business-class Airfare for Two on American Airlines to Kona, HI
  • A Dolphin Swim Adventure for Two
  • A Manta Ray Night Snorkel for Two
  • A Scuba Instruction Package for Two

Only 1000 raffle tickets will be sold @ $50 each: first-come, first-served.

All proceeds will benefit International Myeloma Foundation Research and Programs. Visit the link below to learn more.

LearnMoreButton.png

| EDUCATION | Teleconference

250x250teleconference.jpg

| INSPIRATION | Father’s Day

250x250amazonFathersDay.jpg

Register Now for the Post-ASCO/EHA/IMWG Teleconference
Shop for Dad and Give to the IMF at the Same Time

Dr. Brian G.M. Durie will explain what’s new and exciting from the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA), and International Myeloma Working Group Summit (IMWG). You won’t want to miss this free IMF teleconference followed by a Q & A session!

If you shop Amazon this Father’s Day (Sunday, June 16) or for your daily needs, visit smile.amazon.com and select the International Myeloma Foundation as your preferred charity. When you shop at this link, Amazon will donate a percentage of your total purchase to the IMF, at no added cost to you.

Register Now Button.png

ShopNowButton.png

| ADVOCACY | Action Alert

540x270rayandguest.jpg

IMF Leads Cancer Advocates on Capitol Hill

On Wednesday, June 12, the International Myeloma Foundation’s Advocacy department led a group of cancer advocates to Capitol Hill as a part of efforts of the Coalition to Improve Access to Cancer Care (CIACC) to increase support for the Cancer Drug Parity Act of 2019. The article at the link below explains how you can send a message to Congress to support this legislation.

TakeActionButton.png

| INNOVATION | ASCO Videos

540x270ascoRajkumar.jpg

Watch and Learn About the Latest Research from ASCO 2019

The IMF captured video footage from top myeloma experts at the recent American Society of Clinical Oncology Annual Meeting in Chicago. Of note, Abstract #8003, the phase III CASSIOPEIA study, showed that adding Darzalex (daratumumab) to bortezomib, thalidomide, and dexamethasone (VTd) before and after autologous stem cell transplant “resulted in deeper responses and longer progression-free survival compared to VTd alone in patients with newly diagnosed multiple myeloma who are transplant-eligible."

Also a standout was Abstract #8005, the phase III COLUMBA study. This study looked at subcutaneously administered Darzalex that was co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) in patients with relapsed/refractory multiple myeloma. Learn more about these and other key ASCO abstracts at the link below.

ButtonWatchNow.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox6.13.19.png

CLINICAL TRIALS
EVENTS

Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

June 15, 2019
Regional Community Workshop
Detroit, MI

June 29, 2019
Regional Community Workshop
Pittsburgh, PA

August 1, 2019
Brian D. Novis Research Grants
Apply Now!

August 2, 2019
Laughs for Life
Hattiesburg, MS

August 23-24, 2019
IMF Patient & Family Seminar
Los Angeles, CA

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Celgene Corporation, Genentech, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.